Patents by Inventor László Vígh
László Vígh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10660789Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediType: GrantFiled: February 28, 2019Date of Patent: May 26, 2020Assignee: RICHTER GEDEON NYRT.Inventors: Ferenc Fülöp, László Vígh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
-
Publication number: 20190192336Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediType: ApplicationFiled: February 28, 2019Publication date: June 27, 2019Inventors: Ferenc FÜLÖP, László VÍGH, Zsolt TÖRÖK, Botond PENKE, Ibolya HORVÁTH, Gábor BALOGH, Sándor BERNÁTH, Ákos HUNYA
-
Patent number: 10258498Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediType: GrantFiled: November 22, 2012Date of Patent: April 16, 2019Assignee: Richter Gedeon NYRT.Inventors: Ferenc Fülöp, László Vigh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
-
Publication number: 20150366852Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.Type: ApplicationFiled: June 23, 2015Publication date: December 24, 2015Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Michael Brownstein, Kálmán Takács, Laszlo Vigh, József Mandl, Balázs Sümegi, Sandor Bernath, Attila Kolonics, Gábor Balogh, Janos Egri
-
Publication number: 20140315893Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediType: ApplicationFiled: November 22, 2012Publication date: October 23, 2014Inventors: Ferenc Fülöp, László Vígh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
-
Publication number: 20100311719Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.Type: ApplicationFiled: August 17, 2010Publication date: December 9, 2010Inventors: Péter Literáti Nagy, Jesse Roth, Zoltán Szilvássy, Kálmán Tory, Mike Brownstein, Kálmán Takács, László Vígh, József Mandl, Balázs Sümegi, Sándor Bernáth, Attila Kolonics, Gábor Balogh, János Egri
-
Publication number: 20100267711Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.Type: ApplicationFiled: June 25, 2010Publication date: October 21, 2010Applicant: CytRx CorporationInventors: László Vígh, Péter Literáti Nagy, Jenó Szilbereky, László Ürögdi, Andrea Jednákovits, László Jaszlits, Katalin Bíró, Ede Màrvànyos, Mihály Barabás, Erzsébet Hegedüs, László Korányi, Mária Kürthy, Gábor Balogh, Ibolya Horváth, Zsolt Török, Éva Udvardy, György Dormán, Dénes Medzihradszky, Bea Mézes, Eszter Kovács, Ernó Duda, Beatrix Farkas, Attila Glatz
-
Patent number: 7763601Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime (BGP-15) or a pharmaceutically suitable acid addition salt thereof can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight gain.Type: GrantFiled: March 19, 2007Date of Patent: July 27, 2010Assignee: N-Gene Research Laboratories, Inc.Inventors: Péter Literáti Nagy, Zoltán Szilvássy, Kálmán Tory, László Vígh, Kálmán Takács, József Mandl, Balázs Sümegi, Sándor Bernáth, Attila Kolonics, Gábor Balogh, János Egri
-
Patent number: 7745465Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.Type: GrantFiled: July 10, 2003Date of Patent: June 29, 2010Assignee: CytRx CorporationInventors: László Vígh, Péter Literáti Nagy, Jenö Szilbereky, László Ürögdi, Andrea Jednákovits, László Jaszlits, Katalin Bíró, Ede Márványos, Mihály Barabás, Erzsébet Hegedüs, László Korányi, Mária Kürthy, Gábor Balogh, Ibolya Horváth, Zsolt Török, Éva Udvardy, György Dormán, Dénes Medzihradszky, Bea Mézes, Eszter Kovács, Ernö Duda, Beatrix Farkas, Attila Glatz
-
Publication number: 20090281143Abstract: O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce overweight or obesity and, preferably, reduce one or more unfavourable psychiatric side effects of the cannabinoid CB1 receptor antagonist.Type: ApplicationFiled: December 10, 2008Publication date: November 12, 2009Inventors: Peter Literati Nagy, Zoltan Szilvassy, Kalman Tory, Attila Kolonics, Sandor Bernath, Laszlo Vigh, Jesse Roth, G. Alexander Fleming, Michael Brownstein, Janos Egri
-
Publication number: 20090214677Abstract: An extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is used for the regeneration of the organism of a mammal after long-lasting immobilization, anorexia, states following a disease or accompanied by weight loss as well as for muscle development or muscle growth during muscle developing training, treatment of muscular strain and adaptation to high-altitude as well as for the prevention or treatment of neurodegenerative diseases and/or motility disorders of the gastrointestinal system.Type: ApplicationFiled: August 30, 2006Publication date: August 27, 2009Applicant: ELSO MAGYAR BIODROG KUTATÓ ÉS FEJLESZTO KFTInventors: Péter Literati Nagy, Kalman Tory, Attila Kolonics, Agnes Keri, Lajos Laszlo, Laszlo Jaszlits, Agnes Bajza, Sandor Bernath, Laszlo Vigh, Tibor Bodnar, Janos Egri
-
Publication number: 20090130234Abstract: The invention refers to the use of an extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active agent for the preparation of a pharmaceutical composition suitable for the treatment of diabetic periodontitis.Type: ApplicationFiled: October 10, 2006Publication date: May 21, 2009Inventors: Peter Literati Nagy, Zsolt Lohinai, Kalman Tory, Attila Kolonics, Agnes Keri, Orsolya Rigo, Andras Huszak, Balazs Zahonyi, Sandor Bernath, Laszlo Vigh, Tibor Bodnar, Jonos Egri
-
Publication number: 20080108602Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.Type: ApplicationFiled: March 19, 2007Publication date: May 8, 2008Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Mike Brownstein, Kalman Takacs, Laszlo Vigh, Jozsef Mandi, Balazs Sumegi, Sandor Bernath, Attila Kolonics, Gabor Balogh, Janos Egri
-
Publication number: 20080108673Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight.Type: ApplicationFiled: March 19, 2007Publication date: May 8, 2008Inventors: Peter Literati Nagy, Zoltan Szilvassy, Kalman Tory, Laszlo Vigh, Kalman Takacs, Jozsef Mandl, Balazs Sumegi, Sandor Bernath, Attila Kolonics, Gabor Balogh, Janos Egri
-
Patent number: 7148239Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.Type: GrantFiled: July 10, 2003Date of Patent: December 12, 2006Assignee: CytRx CorporationInventors: László Vígh, Péter Literáti Nagy, Jenó Szilbereky, László Ürögdi, Andrea Jednákovits, László Jaszlits, Katalin Bíró, Ede Márványos, Mihály Barabás, Erzsébet Hegedüs, László Korányi, Mária Kürthy, Gábor Balogh, Ibolya Horváth, Zsolt Török, Éva Udvardy, György Dormán, Dénes Medzihradszky, Bea Mézes, Eszter Kovács, Ernó Duda, Beatrix Farkas, Attila Glatz
-
Patent number: 6884424Abstract: The invention relates to methods for prevention and/or treatment of skin lesions caused by exposure to ultraviolet radiation. Exemplary condition that can be prevented or treated are actinic keratosis, dry skin, polymorphic light exanthema, photopathology, photo-allergy, solar atrophy, stria migrans, elastoma diffusum, X-ray dermatitis, gouty polychondritis and decubitis ulcer.Type: GrantFiled: December 7, 2001Date of Patent: April 26, 2005Assignee: N-Gene Research Laboratories Inc.Inventors: Bea Farkas, Peter Literati Nagy, Agnes Vadasz, Laszlo Vigh
-
Publication number: 20040067940Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.Type: ApplicationFiled: July 10, 2003Publication date: April 8, 2004Applicant: Biorex Research & Development Co.Inventors: Laszlo Vigh, Peter Literati Nagy, Jeno Szilbereky, Laszlo Urogdi, Andrea Jednakovits, Laszlo Jaszlits, Katalin Biro, Ede Marvanyos, Mihaly Barabas, Erzsebet Hegedus, Laszlo Koranyi, Maria Kurthy, Gabor Balogh, Ibolya Horvath, Zsolt Torok, Eva Udvardy, Gyorgy Dorman, Denes Medzihradszky, Bea Mezes, Eszter Kovacs, Erno Duda, Beatrix Farkas, Attila Glatz
-
Publication number: 20040019103Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II).Type: ApplicationFiled: July 10, 2003Publication date: January 29, 2004Applicant: Biorex Research & Development Co.Inventors: Laszlo Vigh, Peter Literati Nagy, Jeno Szilbereky, Laszlo Urogdi, Andrea Jednakovits, Laszlo Jaszlits, Katalin Biro, Ede Marvanyos, Mihaly Barabas, Erzsebet Hegedus, Laszlo Koranyi, Maria Kurthy, Gabor Balogh, Ibolya Horvath, Zsolt Torok, Eva Udvardy, Gyorgy Dorman, Denes Medzihradszky, Bea Mezes, Eszter Kovacs, Erno Duda, Beatrix Farkas, Attila Glatz
-
Patent number: 6653326Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively; an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxyl amine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.Type: GrantFiled: December 7, 1999Date of Patent: November 25, 2003Assignee: Biorex Research & Development Co.Inventors: László Vígh, Péter Literáti Nagy, Jenó Szilbereky, László Ürögdi, Andrea Jednákovits, László Jaszlits, Katalin Bíró, Ede Màrvànyos, Mihály Barabás, Erzsébet Hegedüs, László Korányi, Mária Kürthy, Gábor Balogh, Ibolya Horváth, Zsolt Török, Éva Udvardy, György Dormán, Dénes Medzihradszky, Bea Mézes, Eszter Kovács, Ernö Duda, Beatrix Farkas, Attila Glatz
-
Patent number: 6458371Abstract: A novel cosmetic composition comprising a known hydroximic acid derivative as the active ingredient, and conventional carriers of the cosmetic composition are disclosed. The cosmetic composition of the invention is suitable for the prevention and/or reduction of the photoaging processes of the skin exposed to UV radiation.Type: GrantFiled: December 4, 1998Date of Patent: October 1, 2002Assignee: Medgene, LimitedInventors: Bea Farkas, Peter Literati Nagy, Agnes Vadasz, Laszlo Vigh